Search
Close this search box.

A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

76

Trial Chairperson

Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD

Clinical Trial Registration

Related Post

Trek4TROG team 2024 in Blue Mountains
13 November, 2024

Trek4TROG team rise to Blue Mountains challenge

November 2024: Congratulations to the Trek4TROG team for successfully

24 October, 2024

Promising new results from RAIDER trial published

24 October 2024: Newly published findings from the TROG